Holen Sie sich die Stockscreener-App
26.09
1.72%
0.44
Handel nachbörslich:
26.09
Schlusskurs vom Vortag:
$25.65
Offen:
$25.43
24-Stunden-Volumen:
622.68K
Relative Volume:
2.78
Marktkapitalisierung:
$879.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.36%
1M Leistung:
-4.82%
6M Leistung:
+57.17%
1J Leistung:
+0.00%
1-Tages-Spanne:
$25.23
$26.69
1-Wochen-Bereich:
$25.01
$27.66
52-Wochen-Spanne:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
26.09 | 879.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
(AVBP) Investment Analysis - Stock Traders Daily
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in A - GuruFocus.com
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9% - MarketBeat
Suvretta Capital Management LLC Purchases 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Trading Report - Stock Traders Daily
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent Biopharma Inc (AVBP) Stock Price & Chart | Trade Now - Capital.com
ArriVent BioPharma (NASDAQ:AVBP) Receives Buy Rating from HC Wainwright - MarketBeat
ArriVent BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
ArriVent Reports $282.9M Cash Position, Firmonertinib Shows Promise in NSCLC Trial | AVBP Stock News - StockTitan
FMR LLC's Strategic Acquisition of ArriVent BioPharma Inc Shares - GuruFocus.com
(AVBP) On The My Stocks Page - Stock Traders Daily
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MSN
AlphaCentric Advisors LLC Cuts Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Long Term Trading Analysis for (AVBP) - Stock Traders Daily
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month HighShould You Buy? - MarketBeat
ArriVent To Present FURTHER Data At The 2024 World Conference On Lung Cancer - RTTNews
When the Price of (AVBP) Talks, People Listen - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 80.1% in September - MarketBeat
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc - Yahoo Finance
(AVBP) Proactive Strategies - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3% - MarketBeat
Novo Holdings A S Buys 422,860 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.4% in September - MarketBeat
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4% - MarketBeat
Regeneron purchases former Quad Graphics site in Saratoga Springs - MSN
How to Take Advantage of moves in (AVBP) - Stock Traders Daily
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Simply Wall St
Bank of New York Mellon Corp Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - MarketBeat
It makes sense and dollars to buy ArriVent BioPharma Inc. (AVBP) stock - SETE News
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94 - Defense World
Was ArriVent BioPharma Inc. (AVBP)’s session last reading good? - US Post News
Closing Figures: ArriVent BioPharma Inc. (AVBP)’s Positive Finish at 24.20, Up 2.59 - The Dwinnex
ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Es liegen keine Finanzdaten für Arrivent Biopharma Inc (AVBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMEN | 10% Owner |
Jan 30 '24 |
Buy |
18.00 |
555,555 |
9,999,990 |
4,484,672 |
| ORBIMED ADVISORS LLC | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| GORDON CARL L | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| HEALY JAMES | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,696,752 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):